| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD7-M52H3 | Mouse | Mouse CD7 Protein, His Tag |  |
|
|
| CD7-HF258 | Human | FITC-Labeled Human CD7 Protein, Fc Tag |  |
|
|
| CD7-HP2E3 | Human | PE-Labeled Human CD7 Protein, His Tag (Site-specific conjugation) |  |
||
| CD7-H82F3 | Human | Biotinylated Human CD7 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| CD7-H5253 | Human | Human CD7 Protein, Fc Tag (MALS verified) |  |
|
|
| CD7-H82E4 | Human | Biotinylated Human CD7 Protein, His,Avitag™ |  |
|
|
| CD7-HF257 | Human | FITC-Labeled Human CD7 Protein, Llama IgG2b Fc Tag |  |
|
|
| CD7-HF2H6 | Human | FITC-Labeled Human CD7 Protein, His Tag |  |
|
|
| CD7-H52H7 | Human | Human CD7 Protein, His Tag (MALS verified) |  |
|
|
| CD7-H5258 | Human | Human CD7 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
5e5 of anti-CD7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD7 Protein, His Tag(Cat. No. CD7-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human CD7, Fc,Avitag (Cat. No. CD7-H82F3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD7 antibody, Mouse IgG1 with a linear range of 1-2 ng/mL (QC tested).
The purity of Biotinylated Human CD7, Fc,Avitag(Cat. No. CD7-H82F3) is more than 90% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD7 targeted CAR-γδ T Cells (Persongen Bio) | Phase 1 Clinical | Leukemia, B-Cell | Details | ||
| GC-027 | GC-027 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD7 CARvac T cell therapy | Icell Gene Therapeutics | Details | |||
| CTD-401 | CTD-401; CTD401 | Clinical | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD7 universal CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Xinqiao Hospital, Army Medical University | Lymphoma, T-Cell; Leukemia, T-Cell | Details | |
| CD7-CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd, The First Affiliated Hospital Of Zhengzhou University | Enteropathy-Associated T-Cell Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell | Details | |
| SenL-T7 CAR T Cells (Hebei Senlang Biological) | Details | ||||
| CAR7-T Cell Therapy (Beijing Gaobo Biotechnology Co Ltd) | Phase 1 Clinical | Lymphoma, T-Cell; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | ||
| Humanized CD7 CAR-T cells | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Lymphoma, T-Cell | Details | |
| RD13-01 | RD13-01 | Clinical | Zhejiang University | Hematologic Neoplasms | Details |
| Anti-Cd7 chimeric antigen receptor natural killer cell therapy (PersonGen Biomedicine) | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia; Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Leukemia, Large Granular Lymphocytic | Details | |
| Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate | HENO-3; SPV-T3a | Phase 3 Clinical | Xenikos | Graft vs Host Disease | Details |
| PA3-17 | PA3-17; PA-3-17 | Phase 1 Clinical | Persongen Anke Cell Technology Co Ltd, Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
| This CAR-T-7 cells therapy | This CAR-T-7 cells | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell | Details |
| Anti-CD7 CAR T-cell therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia; Lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
